Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer

Figure 1 Immunohistochemical staining for galectin-1 and vascular endothelial growth factor (original magnification, × 200). A: Positive galectin-1 expression in gastric cancer tissue; B: Positive vascular endothelial growth factor expression in gastric cancer tissue. The over-expressed markers are shown with arrows.

Figure 2 Vascular endothelial growth factor was expressed more frequently in galectin-1-positive gastric cancers than galectin-1-negative.

Figure 3 Overall survival rate of patients. A: The overall survival rate of patients relative to galectin-1-positive expression and galectin-1-negative expression in gastric cancer tissue samples. Galectin-1 overexpression was significantly associated with poor patient survival (P < 0.05); B: The overall survival rate of patients relative to vascular endothelial growth factor-positive expression and vascular endothelial growth factor -negative expression in gastric cancer tissue samples. Vascular endothelial growth factor overexpression was significantly associated with poor patient survival (P < 0.05); C: The overall survival rates of patients relative to groups I, II, III and IV. Both galectin-1 and vascular endothelial growth factor overexpression was significantly associated with poor patient survival (P < 0.05).